Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors

Lentiviral vectors enable durable gene correction in hematopoietic stem cells but carry a risk of insertional mutagenesis, potentially leading to clonal expansion and hematologic malignancies. This review examines the mechanisms underlying this risk, recent clinical safety signals, and strategies to improve the safety of gene therapy. Here, we review evidence from clinical trials, mechanistic studies, and preclinical research, focusing on vector integration, promoter activity, clonal hematopoiesis, and treatment-related factors influencing leukemogenesis. Insertional mutagenesis can alter gene expression through enhancer-mediated activation, aberrant transcript formation, and disruption of endogenous regulatory elements. Recent cases of myelodysplastic syndrome and acute leukemia following gene therapy for cerebral adrenoleukodystrophy have highlighted the potential genotoxicity of strong internal promoters, particularly MND. However, outcomes in adenosine deaminase-deficient severe combined immunodeficiency suggest that oncogenic risk is context-dependent. Disease biology, patient age, pre-existing somatic mutations, vector copy number, conditioning regimens, and post-transplant clonal selection may interact to influence malignancy development. In conclusion, insertional mutagenesis remains a clinically relevant challenge despite advances in lentiviral vector design. Integration site analysis and emerging statistical tools, including MELISSA, may facilitate earlier detection of potentially hazardous clonal expansion. Improving safety requires optimized promoter selection, reduced vector copy numbers, enhanced preclinical assessment, individualized risk stratification, and comprehensive long-term surveillance that integrates vector insertion and somatic mutation analyses.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-16
DOI
https://doi.org/10.3390/cancers18223664
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors

Frank J. T. Staal, Christ Leemans, Karin Pike‐Overzet
1 links
Cancers
Virus-based gene therapy research
article

Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors

Frank J. T. Staal, Christ Leemans, Karin Pike‐Overzet
article en

Abstract

Lentiviral vectors enable durable gene correction in hematopoietic stem cells but carry a risk of insertional mutagenesis, potentially leading to clonal expansion and hematologic malignancies. This review examines the mechanisms underlying this risk, recent clinical safety signals, and strategies to improve the safety of gene therapy. Here, we review evidence from clinical trials, mechanistic studies, and preclinical research, focusing on vector integration, promoter activity, clonal hematopoiesis, and treatment-related factors influencing leukemogenesis. Insertional mutagenesis can alter gene expression through enhancer-mediated activation, aberrant transcript formation, and disruption of endogenous regulatory elements. Recent cases of myelodysplastic syndrome and acute leukemia following gene therapy for cerebral adrenoleukodystrophy have highlighted the potential genotoxicity of strong internal promoters, particularly MND. However, outcomes in adenosine deaminase-deficient severe combined immunodeficiency suggest that oncogenic risk is context-dependent. Disease biology, patient age, pre-existing somatic mutations, vector copy number, conditioning regimens, and post-transplant clonal selection may interact to influence malignancy development. In conclusion, insertional mutagenesis remains a clinically relevant challenge despite advances in lentiviral vector design. Integration site analysis and emerging statistical tools, including MELISSA, may facilitate earlier detection of potentially hazardous clonal expansion. Improving safety requires optimized promoter selection, reduced vector copy numbers, enhanced preclinical assessment, individualized risk stratification, and comprehensive long-term surveillance that integrates vector insertion and somatic mutation analyses.

CancersVol. 18(22)
Leiden University Medical Center (NL), Novo Nordisk Foundation Center for Stem Cell Medicine (DK)
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon